Change over period: —
NSE · BLISSGVS
BLISSGVS PH
-7.8% from the 52-week high · +376.6% above the low
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 763 full-time employees. The company went IPO on 2010-07-26. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
The short version. BLISSGVS PH reported revenue of ₹313 crore for Sep 2026, up 28.3% from a year earlier. Net profit was ₹52 crore (up 92.6% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 50.07% in Sep 2026, up 14.97 points over 8 quarters.
1 · The price
How has the stock traded?
BLISSGVS PH trades 7.8% below its 52-week high and 376.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹313 cr.
Sep 2026 net profit of ₹52 cr.
5.6 pts higher than a year earlier.
Revenue compounded at 9.2% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 313 | 286 | 257 | 218 | 244 | 207 | 198 | 210 |
| Net profit | 52 | 50 | 36 | 23 | 27 | 43 | 16 | 24 |
| Net margin % | 16.7 | 17.5 | 13.8 | 10.7 | 11.1 | 20.7 | 7.8 | 11.3 |
| EPS (₹) | 4.91 | 4.72 | 3.36 | 2.2 | 2.58 | 4.08 | 1.47 | 2.26 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 927 | 810 | 770 | 752 | 747 | 577 | 689 | 898 |
| Net profit | 129 | 84 | 75 | 71 | 15 | 68 | 97 | 124 |
| Net margin % | 13.9 | 10.4 | 9.8 | 9.4 | 2.0 | 11.9 | 14.1 | 13.8 |
| EPS (₹) | 12.21 | 8.0 | 7.21 | 6.8 | 1.45 | 6.64 | 9.43 | 12.96 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 10.8% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 10.8 | 8.0 | 7.8 | 8.0 |
| Return on capital % | 16.0 | 11.8 | 11.7 | 12.1 |
| EBITDA margin % | 23.5 | 19.3 | 18.8 | 17.6 |
| Net margin % | 12.9 | 10.0 | 9.4 | 9.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.2% | 10.9% |
| Profit CAGR | 22.1% | 13.5% |
4 · The owners
Who holds it, and are they adding?
Up 14.97 pts over 8 quarters.
Down 8.48 pts over 8 quarters.
Up 3.07 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 35.1 | 35.29 | 35.44 | 35.39 | 35.36 | 35.36 | 35.01 | 50.07 | +14.97 |
| FII | 13.51 | 13.18 | 12.65 | 13.27 | 14.54 | 10.45 | 8.07 | 5.03 | -8.48 |
| DII | 6.55 | 6.55 | 6.54 | 5.98 | 5.78 | 5.04 | 9.47 | 9.62 | +3.07 |
| Public | 44.84 | 44.98 | 45.36 | 45.36 | 44.32 | 49.15 | 47.45 | 35.28 | -9.56 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.27% of NAV
- Bandhan BSE Healthcare Index Fund0.27% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for BLISSGVS PH are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about BLISSGVS PH
What is the BLISSGVS PH share price?
BLISSGVS PH (BLISSGVS) last closed at ₹665.35, down 2.2% on the day. Its 52-week range is ₹142.76 to ₹737.65.
What is the market cap of BLISSGVS PH?
BLISSGVS PH has a market capitalisation of about ₹7,170 crore. Its price-to-earnings ratio is 45.7.
How are BLISSGVS PH's latest results?
BLISSGVS PH reported revenue of ₹313 crore for Sep 2026, up 28.3% from a year earlier. Net profit was ₹52 crore (up 92.6% year on year). Return on equity was 10.8% in Mar 2026. Promoter holding was 50.07% in Sep 2026, up 14.97 points over 8 quarters.
Who owns BLISSGVS PH?
As of Sep 2026, shareholding was: Promoter 50.07%, FII 5.03%, DII 9.62%, Public 35.28%.
How many mutual funds hold BLISSGVS PH?
2 mutual fund schemes held BLISSGVS PH in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 08 Jul 2026 · Final Dividend - Rs. 1
- 18 Feb 2026 · Interim Dividend - Rs. 0.5
- 24 Jul 2025 · Final Dividend - Rs. 0.5
- 18 Jul 2024 · Final Dividend - Rs. 0.5
- 12 Jul 2023 · Final Dividend - Rs. 0.5
- 20 Jun 2022 · Final Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.